Prevalence of <i>EGFR</i> Mutations in Patients With Resected Stage I to III Nonsquamous Non–Small Cell Lung Cancer: Results of India Cohort
EARLY-EGFR India results showed the prevalence of <i>EGFR</i> mutation to be 26%. The study emphasized the pressing need for up-front biomarker testing at diagnosis to ensure optimal and timely personalized treatment.
Authors
- Sajjan Rajpurohit
- Vanita Noronha (ORCID: https://orcid.org/0000-0002-0191-2744)
- Sachin Khurana (ORCID: https://orcid.org/0000-0002-6308-5481)
- Rajesh Mistry
- Bhavesh Poladia
- Ramakant Deshpande (ORCID: https://orcid.org/0000-0003-0292-527X)
- Vivek Agarwala (ORCID: https://orcid.org/0000-0003-1381-0320)
- Ullas Batra (ORCID: https://orcid.org/0000-0003-3306-9824)
- Kumar Prabhash (ORCID: https://orcid.org/0000-0001-8858-5004)
- Mansi Sharma (ORCID: https://orcid.org/0000-0001-9940-8724)
- Gull Mohammad Bhat
- Saquib Zaffar Banday
Institutions
- All India Institute of Medical Sciences Raipur (IN)
- Sher-i-Kashmir Institute of Medical Sciences (IN)
- Tata Memorial Hospital (IN)
- NIMS University (IN)
- Cancer Institute (WIA) (IN)
- Max Super Speciality Hospital (IN)
- Narayana Health (IN)
- Rajiv Gandhi Cancer Institute and Research Centre (IN)
- All India Institute of Medical Sciences Bhopal (IN)
- Kokilaben Dhirubhai Ambani Hospital (IN)
- All India Institute of Medical Sciences (IN)
Publication Details
- Journal
- JCO Global Oncology
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1200/go-24-00353
- Citations
- 3
- Primary Topic
- Lung Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 4.56